Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage cases that can be ...

Roche, one of our most tenured partners, gained two significant regulatory approvals with the FDA approval for TECENTRIQ subcutaneous within ENHANZE and for OCREVUS subcutaneous within ENHANZE.

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

“In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche’s TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE’s track record of 100% phase 3 ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

Roche announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San ...